Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment

Pei-Yu Kuo, MS, Violetta V. Leshchenko, PhD, Melissa J Fazzari, PhD, Tobias A. Gellen, Javeed Iqbal, M.Sc, PhD, Stefanie Baumgartner-Wennerholm, MD, Lina Nygren, MD, K. Stephen Suh, PhD, Andre Goy, MD, David T. Yang, MD, Wing-Chung Chan, MD, Brad S Kahl, MD, Amit Verma, MD, Randy D. Gascoyne, MD, Eva Kimby, M.D., Ph.D., Birgitta Sander, MD, Ph.D., B. Hilda Ye, PhD, Ari Melnick, MD, Samir Parekh, MD

Blood (2012) 120 (21): 895.

https://doi.org/10.1182/blood.V120.21.895.895

Published: 2012

Journal Articles

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

Eva Kimby, M.D., Ph.D., Björn Östenstad, Peter de Nully Brown, Harald Holte, Jr., MD, PhD, Hans Hagberg, Martin Erlanson, Ola Linden, MD, Marie Nordström, MD, PhD, Christer Sundstrom, MD, PhD

Blood (2012) 120 (21): 794.

https://doi.org/10.1182/blood.V120.21.794.794

Published: 2012

Journal Articles

Immunochemotherapy with Low-Dose Subcutaneous Alemtuzumab (A) Plus Oral Fludarabine and Cyclophosphamide (FC) Is Safe and Induces More and Deeper Complete Remissions in Untreated Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Than Chemotherapy with FC Alone. An Early Analysis of the Randomized Phase-III HOVON68 CLL Trial

Christian H Geisler, MD, PhD, Mars MB van 't Veer, MD, PhD, Wim van Putten, MSc, Jesper Jurlander, MD.PHD, Jan Walewski, MD, PhD, Geir Tjonnfjord, MD, PHD, Maija Itälä-Remes, MD, PHD, Eva Kimby, M.D., Ph.D., Tomas Kozak, MD, PhD, Aaron Polliack, MD, Shulamiet Wittebol, MD, Fokje Spoelstra, PhD, Marinus H.J. Van Oers, MD, PhD

Blood (2011) 118 (21): 290.

https://doi.org/10.1182/blood.V118.21.290.290

Published: 2011

Journal Articles

SOX11 Expression Versus Indolent Clinical Course in Mantle Cell Lymphomas in a Population-Based Cohort From the Stockholm Region – SOX11 Negative Tumors Are Mostly p53 Positive, Contributing to Shorter Overall Survival,

Birgitta Sander, MD, Ph.D., Monika Klimkowska, MD., Ph.D., Lina Nygren, MD, Stefanie Baumgartner, MD, Birger Christensson, M.D., Ph.D., Eva Kimby, M.D., Ph.D.

Blood (2011) 118 (21): 3651.

https://doi.org/10.1182/blood.V118.21.3651.3651

Published: 2011

Journal Articles

Prognostic Impact of Clinical and Tumor Associated Variables in a Population-Based Cohort of Mantle Cell Lymphomas in the Stockholm Region Between 1998–2010

Stefanie Baumgartner Wennerholm, MD, Monika Klimkowska, MD., Ph.D., Lina Nygren, MD, Eva Kimby, M.D., Ph.D., Birgitta Sander, MD, Ph.D.

Blood (2011) 118 (21): 1592.

https://doi.org/10.1182/blood.V118.21.1592.1592

Published: 2011

Journal Articles

Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab

Björn Engelbrekt Wahlin, MD, PhD, Christer Sundström, Harald Holte, Birgitta Sander, MD, Ph.D., Bjørn Østenstad, Peter de Nully Brown, Erlend B. Smeland, Jan Delabie, Birger Christensson, M.D., Ph.D., Eva Kimby, M.D., Ph.D.

Blood (2011) 118 (21): 1641.

https://doi.org/10.1182/blood.V118.21.1641.1641

Published: 2011

NARROW

SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

SOX11 Expression Versus Indolent Clinical Course in Mantle Cell Lymphomas in a Population-Based Cohort From the Stockholm Region – SOX11 Negative Tumors Are Mostly p53 Positive, Contributing to Shorter Overall Survival,

Prognostic Impact of Clinical and Tumor Associated Variables in a Population-Based Cohort of Mantle Cell Lymphomas in the Stockholm Region Between 1998–2010

Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab

Email alerts

ASH Publications

American Society of Hematology

SOX11 Directly Represses Wnt/β-Catenin Signaling and Identifies a Subgroup of Mantle Cell Lymphoma Patients with Improved Survival with Intensive Treatment

Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group

SOX11 Expression Versus Indolent Clinical Course in Mantle Cell Lymphomas in a Population-Based Cohort From the Stockholm Region – SOX11 Negative Tumors Are Mostly p53 Positive, Contributing to Shorter Overall Survival,

Prognostic Impact of Clinical and Tumor Associated Variables in a Population-Based Cohort of Mantle Cell Lymphomas in the Stockholm Region Between 1998–2010

Increasing Grades of Follicular Lymphoma Correlate with Better Prognosis in Patients Treated with Rituximab

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only